PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31627812-4 2019 The multi-functionalized composite - ssDNA-AuNPs/IGA3/SiO2@ GOAG was obtained and used to construct the CL biosensor for insulin detection. Silicon 54-58 insulin Homo sapiens 121-128 33330897-0 2021 Bioinspired zwitterionic polyphosphoester modified porous silicon nanoparticles for efficient oral insulin delivery. Silicon 58-65 insulin Homo sapiens 99-106 29855134-0 2018 Engineered Multifunctional Albumin-Decorated Porous Silicon Nanoparticles for FcRn Translocation of Insulin. Silicon 52-59 insulin Homo sapiens 100-107 30991018-0 2019 Rapid detection of insulin by immune-enrichment with silicon-nanoparticle-assisted MALDI-TOF MS. BACKGROUND: Insulin is central to regulating fat and carbohydrate metabolism in the body. Silicon 53-60 insulin Homo sapiens 19-26 30991018-0 2019 Rapid detection of insulin by immune-enrichment with silicon-nanoparticle-assisted MALDI-TOF MS. BACKGROUND: Insulin is central to regulating fat and carbohydrate metabolism in the body. Silicon 53-60 insulin Homo sapiens 109-116 30991018-3 2019 Our aim was to establish a method to detect insulin using silicon nanoparticle-assisted high-throughput MS. METHODS: Different nanomaterials with the potential for use as MALDI components to enhance the MS signal by increasing peptide ionization were investigated in the present study. Silicon 58-65 insulin Homo sapiens 44-51 30991018-4 2019 Insulin in samples was enriched with antibody-coated silicon nanoparticles and then analyzed by MALDI-TOF MS. Silicon 53-60 insulin Homo sapiens 0-7 30991018-7 2019 The silicon nanoparticle-MS assay exhibited high sensitivity (LOQ, 0.1 nM) and good linear correlation of MS intensity with insulin concentration (R2 = 0.99). Silicon 4-11 insulin Homo sapiens 124-131 30991018-10 2019 CONCLUSIONS: In our study, we found that the insulin signal could be enhanced with silicon nanoparticles. Silicon 83-90 insulin Homo sapiens 45-52 29855134-4 2018 In this study, a novel nanoparticulate system for insulin delivery based on porous silicon NPs is proposed. Silicon 83-90 insulin Homo sapiens 50-57 30393315-0 2018 In Vivo Experimental Study of Noninvasive Insulin Microinjection through Hollow Si Microneedle Array. Silicon 80-82 insulin Homo sapiens 42-49 23500371-0 2013 Silicon multi-nanochannel FETs to improve device uniformity/stability and femtomolar detection of insulin in serum. Silicon 0-7 insulin Homo sapiens 98-105 29104511-8 2017 In addition to BAPTA-AM and W7, L-NAME, an eNOS antagonist, abolished insulin-induced Akt phosphorylation at Ser473 in both si-Neg and si-ATP2B1-transfected endothelial cells. Silicon 124-126 insulin Homo sapiens 70-77 25991649-1 2015 Recently, a model was proposed to assess hepatic insulin sensitivity during a meal, i.e., the ability of insulin to suppress glucose production (EGP), SI (P). Silicon 151-153 insulin Homo sapiens 49-56 24844163-0 2014 Chitosan-modified porous silicon microparticles for enhanced permeability of insulin across intestinal cell monolayers. Silicon 25-32 insulin Homo sapiens 77-84 28082240-0 2017 Non-invasive, in vitro analysis of islet insulin production enabled by an optical porous silicon biosensor. Silicon 89-96 insulin Homo sapiens 41-48 28082240-1 2017 A label-free porous silicon (pSi) based, optical biosensor, using both an antibody and aptamer bioreceptor motif has been developed for the detection of insulin. Silicon 20-27 insulin Homo sapiens 153-160 22610603-0 2012 Development of SI-traceable C-peptide certified reference material NMIJ CRM 6901-a using isotope-dilution mass spectrometry-based amino acid analyses. Silicon 15-17 insulin Homo sapiens 28-37 23450052-9 2013 PCOS women with Si below the PCOS median (more insulin resistant) had a lower mean Sg than controls with Si above the control median (more insulin sensitive). Silicon 16-18 insulin Homo sapiens 47-54 21127982-4 2011 We have discovered that a hydrophobic silicon or glass surface can be made to continuously fibrillate solutions of insulin monomers under stressed conditions (pH 1.6, 65 C). Silicon 38-45 insulin Homo sapiens 115-122 21855304-5 2011 Our results show that mesoporous silicon microparticles prepared by electrochemical methods present moderate affinity for insulin and high affinity for albumin. Silicon 33-40 insulin Homo sapiens 122-129 21855304-8 2011 Mesoporous silicon microparticles with mean pore size of 35 nm released the loaded insulin quickly, but not instantaneously. Silicon 11-18 insulin Homo sapiens 83-90 12608544-3 2003 RESULTS: The flux of FITC-insulin from silicon particles across cell monolayers was nearly 10-fold higher compared with liquid formulations with permeation enhancer and approximately 50-fold compared with liquid formulations without enhancer. Silicon 39-46 insulin Homo sapiens 26-33 19441290-2 2009 The nanocomposite film on silicon was suitable for use as a material for matrix-free LDI-MS of peptides due to its low matrix background from Au clusters and high ionization efficiency; this plate successfully ionized angiotensin I, and also insulin in the proton adduct forms, in contrast to methods using only AuNPs and those using nanocomposite films of cationic polymer in conjunction with Au NPs. Silicon 26-33 insulin Homo sapiens 242-249 12608544-0 2003 Microfabricated porous silicon particles enhance paracellular delivery of insulin across intestinal Caco-2 cell monolayers. Silicon 23-30 insulin Homo sapiens 74-81 14708365-3 2003 According to the SI index, a lower tissue sensitivity to insulin was detected in 48 (87%) of patients; it is noteworthy, that a low SI index was registered in some of them, when indirect signs of insulin-resistance, like hyperglycemia, hyperinsulinemia, were absent. Silicon 17-19 insulin Homo sapiens 57-64 12164703-3 2002 We present insulin and lysozyme results from samples introduced into the vacuum through a micromachined silicon injector, and from samples consisting of a glycerol droplet deposited directly on the sample holder at the high voltage stage of the ion optics. Silicon 104-111 insulin Homo sapiens 11-18 12050270-9 2002 Whole-body glucose disposal and insulin sensitivity (SI clamp) derived from both clamps and normalized for total or visceral fat and lean mass were significantly correlated (r, 0.45-0.65; P < 0.05). Silicon 53-55 insulin Homo sapiens 32-39 9814997-5 1998 Older subjects were insulin resistant (SI: 4.6 +/- 0.8 vs. 8.6 +/- 1.4 x 10(-5) min-1/pM, P < 0.05). Silicon 39-41 insulin Homo sapiens 20-27 10902785-7 2000 We defined a quantitative insulin sensitivity check index (QUICKI = 1/[log(I(0)) + log(G(0))]) that has substantially better correlation with SI(Clamp) (r = 0.78) than the correlation we observed between SI(MM) and SI(Clamp). Silicon 142-144 insulin Homo sapiens 26-33 7934980-4 1994 The low-Si (most insulin-resistant) group had more central body fat distribution (subscapular/triceps skinfold thickness) and a higher median body mass index (BMI) of 26.8 (range, 21.1 to 41.1) kg.m-2 compared with the middle- and high-Si groups with BMIs of 24.9 (19.1 to 31.5) and 23.7 (18.8 to 33.2) kg.m-2 (P < .05). Silicon 8-10 insulin Homo sapiens 17-24 7924144-7 1993 Si was calculated as the index of insulin sensitivity from (Min) and (Mod) and CIGMA was obtained as previously described. Silicon 0-2 insulin Homo sapiens 34-41 34820572-0 2022 Neonatal Fc receptor-targeted lignin-encapsulated porous silicon nanoparticles for enhanced cellular interactions and insulin permeation across the intestinal epithelium. Silicon 57-64 insulin Homo sapiens 118-125